Table 3.
Subgroup analysis of the included studies.
| N | Sensitivity (95% CI) | I2 (%) | Specificity (95% CI) | I2 (%) | PLR (95% CI) | I2 (%) | NLR (95% CI) | I2 (%) | DOR (95% CI) | I2 (%) | AUC | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| rSLEDAI score | ||||||||||||
| > 0 | 4 | 0.66 (0.57–0.75) | 65.1 | 0.77 (0.68–0.84) | 88.8 | 3.80 (1.29–11.22) | 82.8 | 0.44 (0.35–0.57) | 4.1 | 8.90 (3.79–20.98) | 29.6 | 0.79 |
| > 4 | 3 | 0.85 (0.76–0.91) | 80.4 | 0.74 (0.61–0.84) | 68.3 | 3.39 (1.59–7.22) | 61.2 | 0.20 (0.08–0.55) | 62.6 | 19.00 (6.38–56.55) | 7.7 | 0.90 |
| Sample type | ||||||||||||
| Urine | 7 | 0.67 (0.60–0.73) | 87.3 | 0.83 (0.77–0.89) | 63.2 | 3.71 (2.33–5.91) | 38.0 | 0.38 (0.25–0.60) | 77.3 | 12.40 (6.65–23.13) | 0 | 0.86 |
| Serum | 2 | 0.81 (0.67–0.91) | 0 | 0.57 (0.42–0.70) | 79.8 | 2.21 (0.84–5.84) | 69.8 | 0.33 (0.18–0.63) | 0 | 6.56 (1.73–24.94) | 42.6 | NA |
rSLEDAI: renal systemic lupus erythematosus disease activity index; N: number of studies; CI: confidence interval; PLR: positive likelihood ratio; NLR: negative likelihood ratio; DOR: diagnostic odds ratio; AUC: area under the receiver operating characteristic curve; NA: not available.